High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease

Richard K. Burt*, Ann Traynor, Yu Oyama, Robert Craig

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

83 Scopus citations

Abstract

Two patients with severe Crohn disease, defined by a Crohn Disease Activity Index (CDAI) higher than 250 despite anti-tumor necrosis factor α (TNF-α), were treated by intense immune suppression and autologous hematopoietic stem cell transplantation (HSCT). Stem cells were mobilized from the peripheral blood using cyclophosphamide (2.0 g/m2) and granulocyte colony-stimulating factor (G-CSF; 5 μg/kg/d), enriched ex vivo by CD34+ selection, and reinfused after immune conditioning with cyclophosphamide (200 mg/kg) and equine anti-thymocyte globulin (ATG; 90 mg/kg). Patients have remained in remission (CDAI < 100) for 1 year since HSCT. We conclude that further HSCT studies for severe Crohn disease appear warranted.

Original languageEnglish (US)
Pages (from-to)2064-2066
Number of pages3
JournalBlood
Volume101
Issue number5
DOIs
StatePublished - Mar 1 2003

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease'. Together they form a unique fingerprint.

Cite this